Published by Sean Farrell on 4th September 2020
(Sharecast News) - Barclays upgraded Hikma Pharmaceuticals to 'overweight' and increased its price target on the company's shares after a US court ruled in favour of the generic drugmaker's treatment for heart conditions.
URL: http://www.digitallook.com/dl/news/story/31137815/...